Turker Altuntas

Dr. Turker Altuntas

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
MKmehmet umut kutukoglu
mehmet umut kutukoglu
TATurker Altuntas
Turker Altuntas
BŞBahadir Şahi̇n
Bahadir Şahi̇n
AOAhmet Rahmi̇ Onur
Ahmet Rahmi̇ Onur
Background/aim: Sacral neuromodulation (SNM) is a minimally invasive treatment that modulates spinal reflexes to regulate bladder, urinary sphincter, and pelvic floor and has successfully been used in the treatment of refractory voiding dysfunctions. The aim of this study was to present our experience with SNM in a tertiary referral center with the largest number of patients and review the safety and efficacy of the procedure. Materials and methods: A total of 42 patients with refractory lower urinary tract symptoms were included into the study. After an initial test period, patients who showed more than 50% improvement in their symptoms underwent the second stage of SNM. Twelve patients had overactive bladder (OAB), bladder pain syndrome/interstitial cystitis (BPS/IC) and 17 had urinary retention. The clinical success was examined during follow-up by voiding diary, urodynamics, and global response assessment. Results: Between February 2015 and December 2020, a total of 29 patients underwent stages I&II SNM procedures. The mean ages of patients in OAB/BPS group and retention group were 40 (37-57 years) and 35 (27-44 years), respectively. Mean follow-up time was at least 1 year. Overall, 58.5% success rate was observed in OAB, BPS/IC, and urinary retention groups. Global response assessment score in both groups increased significantly (p = 0.001). No statistically significant difference was found between success or failure rates when sex and age were variable parameters (p > 0.05). Conclusion: SNM appears to be an effective and safe treatment option in restoring voiding dysfunctions in patients with refractory idiopathic and neurogenic voiding dysfunctions. Our initial series revealed favorable results; however, further studies with larger series and longer follow-up are needed.


20 December 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
MKmehmet umut kutukoglu
mehmet umut kutukoglu
TATurker Altuntas
Turker Altuntas
CSCagri Akin Sekerci
Cagri Akin Sekerci
SYSultan Seval Yilmaz
Sultan Seval Yilmaz
GHGoncagul Haklar
Goncagul Haklar
SYSelcuk Yucel
Selcuk Yucel
Background: To demonstrate that the CA19-9/creatinine level could be a potential biomarker in children with obstruction by including ureteropelvic junction obstruction (UPJO) patients and comparing them not only with healthy controls but also with children with non-obstructive hydronephrosis (HN). Materials and methods: Children with HN and healthy controls with no HN were prospectively enrolled into study from March 2021 to December 2022. The children with HN were divided into two separate groups. Group 1 consisted of children with UPJO, while Group 2 included children with lower urinary tract dysfunction (LUTD). Data collected from study and control groups included age, gender, spot urine CA 19 − 9/Cr ratio at the initial visit and at the 6-month follow-up, the Society of Fetal Urology (SFU) grade, antero-posterior (AP) diameter, renal function and diuretic response on mercaptoacetyltriglycine (MAG-3) dynamic renal scintigraphy and surgical or conservative management selection. Spot urine CA 19 − 9 levels were measured using the ELISA method. Results: Out of 283 children, Group 1 consisted of 40 children (11 girls, 29 boys; median age: 7 years), Group 2 comprised 18 children (10 girls, 8 boys; median age:8 years) and 225 healthy controls (83 girls, 142 boys; median age: 8 years). The spot urine CA 19 − 9/Cr ratio was significantly higher in the Group 1 and 2 compared to controls (respectively 86.7, 64.5, 47.1 U/mg Cr, p = 0.0001). When the two patient groups with HN were compared with each other, no statistically significant difference was observed in the urinary CA19-9/creatinine levels ( p = 0.358). No correlation was found between CA 19 − 9/Cr ratio and HN severity and/or dynamic renal scintigraphy findings. Surgical management of unilateral UPJO revealed a decrease in CA 19 − 9/Cr in the study group. Conclusion: This study suggests that the spot urine CA 19 − 9/creatinine ratio may serve as a promising, non-invasive biomarker for distinguishing children with unilateral UPJO and non-obstructive HN from healthy controls. Although elevated levels in patients and postoperative decline were observed, its inability to predict HN severity or the necessity for surgical intervention limits its clinical utility. Keywords: CA19-9, biomarker, ureteropelvic junction obstruction, hydronephrosis, lower urinary tract dysfunction

15 October 2025 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
TATurker Altuntas
Turker Altuntas
CSCagri Akin Sekerci
Cagri Akin Sekerci
BBBanu Isbilen Basok
Banu Isbilen Basok
MFMesut Fidan
Mesut Fidan
OOOnur Can Ozkan
Onur Can Ozkan
Tufan TarcanTufan Tarcan
Tufan Tarcan

27 September 2025 in Actas Urológicas Españolas (English Edition)
Verified
Journal Article
Closed access
EGE. Gokmen
E. Gokmen
MKM.U. Kutukoglu
M.U. Kutukoglu
TATurker Altuntas
Turker Altuntas
MKM. Kars
M. Kars
TST.E. Sener
T.E. Sener
YTY. Tanidir
Y. Tanidir

24 February 2026 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
TSTarik Emre Sener
Tarik Emre Sener
NUNaif Dinc Ulker
Naif Dinc Ulker
TATurker Altuntas
Turker Altuntas
EGErsin Gokmen
Ersin Gokmen
ATArman Tsaturyan
Arman Tsaturyan
Olivier TraxerOlivier Traxer
Olivier Traxer
Background and objective: To assess urologists’ perspectives on the impact of lithotomy position on the psoas muscle and ureteral course, and to radiologically evaluate these anatomical changes using a double J (DJ) stent as a marker. Methods: A prospective study was conducted between January and June 2025. An 11-item web-based survey was distributed to fellowship-trained endourologists to explore perceptions regarding lithotomy positioning during ureterorenoscopy. For radiological assessment, adults aged 18–65 who underwent DJ stent placement after ureteroscopy were analyzed using KUB X-rays obtained in supine and standard lithotomy positions. Distances between stent segments and lumbar vertebrae, as well as intersegmental angles, were measured and compared according to BMI. Key findings and limitations: Fifty-three urologists completed the survey. Most reported that psoas muscle length decreases (67.9%) and width increases (66%) in lithotomy position. The standard dorsal lithotomy position was preferred by 60.4%, and 62.3% believed positioning could affect ureteroscope passage at the iliac vessel crossover. Adjustable leg supports were routinely used by 84.9%. Increasing lithotomy level was not considered to significantly influence complication rates (69.8%), operative time (58.5%), or stone-free rates (62.3%). Among 22 radiologically evaluated patients (mean age 51.9 years, 64.6% male), no significant differences were found in stent–vertebra distances or segmental angles between positions, nor across BMI and gender groups. Conclusions and clinical implications: Although radiological analysis showed no measurable ureteral configuration changes, urologists perceive lithotomy positioning as potentially influential during endoscopic access. Further dynamic imaging and outcome-based studies are warranted to clarify its clinical significance.